PIB: A score to select sorafenib treatment candidates for hepatocellular carcinoma in resource-limited settings

Autores
Leathers, James S.; Balderramo, Domingo; Prieto, Jhon; Diehl, Fernando; Gonzalez-Ballerga, Esteban; Ferreiro, Melina R.; Carrera, Enrique; Barreyro, Fernando Javier; Diaz Ferrer, Javier; Singh, Dupinder; Mattos, Angelo Z.; Carrilho, Flair; Debes, Jose D.
Año de publicación
2018
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death globally. Sorafenib, a multi-tyrosine kinase inhibitor, remains the standard of care for patients with inoperable or advanced-stage HCC. In resource-limited settings without access to surgical or locoregional therapy, sorafenib may be the only option for treating HCC. However, due to a modest survival benefit, as well as the limiting cost of sorafenib in certain regions, appropriate selection of patients for treatment is essential. Evaluation of Barcelona Clinic Liver Cancer (BCLC) criteria in resource-limited settings is frequently unachievable due to a variety of reasons. Using a cohort from the South American liver research network (1336 HCC cases), we created a cost-effective prognostic scoring system to help identify patients likely to have a survival benefit on sorafenib treatment, using simple laboratory variable
Fil: Leathers, James S.. Vanderbilt University; Estados Unidos
Fil: Balderramo, Domingo. Universidad de Córdoba; España
Fil: Prieto, Jhon. Centro de Enfermedades Hepáticas y Digestivas; Colombia
Fil: Diehl, Fernando. Universidad de Córdoba; España
Fil: Gonzalez-Ballerga, Esteban. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina
Fil: Ferreiro, Melina R.. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina
Fil: Carrera, Enrique. Hospital Eugenio Espejo; Ecuador
Fil: Barreyro, Fernando Javier. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Nordeste; Argentina
Fil: Diaz Ferrer, Javier. Hospital Nacional Edgardo Rebagliati Martins; Perú
Fil: Singh, Dupinder. University of Minnesota; Estados Unidos
Fil: Mattos, Angelo Z.. Universidade Federal de Ciencias Da Saúde de Porto Alegre; Brasil
Fil: Carrilho, Flair. Universidade de Sao Paulo; Brasil
Fil: Debes, Jose D.. University of Minnesota; Estados Unidos
Materia
HCC
HEPATOCELLULAR CARCINOMA
SCORE
SORAFENIB
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/85699
Acceder
id CONICETDig_81b0c869de45dd9300f460ec1d55c40d
oai_identifier_str oai:ri.conicet.gov.ar:11336/85699
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling PIB: A score to select sorafenib treatment candidates for hepatocellular carcinoma in resource-limited settingsLeathers, James S.Balderramo, DomingoPrieto, JhonDiehl, FernandoGonzalez-Ballerga, EstebanFerreiro, Melina R.Carrera, EnriqueBarreyro, Fernando JavierDiaz Ferrer, JavierSingh, DupinderMattos, Angelo Z.Carrilho, FlairDebes, Jose D.HCCHEPATOCELLULAR CARCINOMASCORESORAFENIBhttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death globally. Sorafenib, a multi-tyrosine kinase inhibitor, remains the standard of care for patients with inoperable or advanced-stage HCC. In resource-limited settings without access to surgical or locoregional therapy, sorafenib may be the only option for treating HCC. However, due to a modest survival benefit, as well as the limiting cost of sorafenib in certain regions, appropriate selection of patients for treatment is essential. Evaluation of Barcelona Clinic Liver Cancer (BCLC) criteria in resource-limited settings is frequently unachievable due to a variety of reasons. Using a cohort from the South American liver research network (1336 HCC cases), we created a cost-effective prognostic scoring system to help identify patients likely to have a survival benefit on sorafenib treatment, using simple laboratory variableFil: Leathers, James S.. Vanderbilt University; Estados UnidosFil: Balderramo, Domingo. Universidad de Córdoba; EspañaFil: Prieto, Jhon. Centro de Enfermedades Hepáticas y Digestivas; ColombiaFil: Diehl, Fernando. Universidad de Córdoba; EspañaFil: Gonzalez-Ballerga, Esteban. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; ArgentinaFil: Ferreiro, Melina R.. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; ArgentinaFil: Carrera, Enrique. Hospital Eugenio Espejo; EcuadorFil: Barreyro, Fernando Javier. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Nordeste; ArgentinaFil: Diaz Ferrer, Javier. Hospital Nacional Edgardo Rebagliati Martins; PerúFil: Singh, Dupinder. University of Minnesota; Estados UnidosFil: Mattos, Angelo Z.. Universidade Federal de Ciencias Da Saúde de Porto Alegre; BrasilFil: Carrilho, Flair. Universidade de Sao Paulo; BrasilFil: Debes, Jose D.. University of Minnesota; Estados UnidosBaqiyatallah Research Center2018-10info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/85699Leathers, James S.; Balderramo, Domingo; Prieto, Jhon; Diehl, Fernando; Gonzalez-Ballerga, Esteban; et al.; PIB: A score to select sorafenib treatment candidates for hepatocellular carcinoma in resource-limited settings; Baqiyatallah Research Center; Hepatitis Monthly; 18; 10; 10-2018; 1-31735-143X1735-3408CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/http://hepatmon.com/en/articles/82345.htmlinfo:eu-repo/semantics/altIdentifier/doi/10.5812/hepatmon.82345info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:59:18Zoai:ri.conicet.gov.ar:11336/85699instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:59:19.198CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv PIB: A score to select sorafenib treatment candidates for hepatocellular carcinoma in resource-limited settings
title PIB: A score to select sorafenib treatment candidates for hepatocellular carcinoma in resource-limited settings
spellingShingle PIB: A score to select sorafenib treatment candidates for hepatocellular carcinoma in resource-limited settings
Leathers, James S.
HCC
HEPATOCELLULAR CARCINOMA
SCORE
SORAFENIB
title_short PIB: A score to select sorafenib treatment candidates for hepatocellular carcinoma in resource-limited settings
title_full PIB: A score to select sorafenib treatment candidates for hepatocellular carcinoma in resource-limited settings
title_fullStr PIB: A score to select sorafenib treatment candidates for hepatocellular carcinoma in resource-limited settings
title_full_unstemmed PIB: A score to select sorafenib treatment candidates for hepatocellular carcinoma in resource-limited settings
title_sort PIB: A score to select sorafenib treatment candidates for hepatocellular carcinoma in resource-limited settings
dc.creator.none.fl_str_mv Leathers, James S.
Balderramo, Domingo
Prieto, Jhon
Diehl, Fernando
Gonzalez-Ballerga, Esteban
Ferreiro, Melina R.
Carrera, Enrique
Barreyro, Fernando Javier
Diaz Ferrer, Javier
Singh, Dupinder
Mattos, Angelo Z.
Carrilho, Flair
Debes, Jose D.
author Leathers, James S.
author_facet Leathers, James S.
Balderramo, Domingo
Prieto, Jhon
Diehl, Fernando
Gonzalez-Ballerga, Esteban
Ferreiro, Melina R.
Carrera, Enrique
Barreyro, Fernando Javier
Diaz Ferrer, Javier
Singh, Dupinder
Mattos, Angelo Z.
Carrilho, Flair
Debes, Jose D.
author_role author
author2 Balderramo, Domingo
Prieto, Jhon
Diehl, Fernando
Gonzalez-Ballerga, Esteban
Ferreiro, Melina R.
Carrera, Enrique
Barreyro, Fernando Javier
Diaz Ferrer, Javier
Singh, Dupinder
Mattos, Angelo Z.
Carrilho, Flair
Debes, Jose D.
author2_role author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv HCC
HEPATOCELLULAR CARCINOMA
SCORE
SORAFENIB
topic HCC
HEPATOCELLULAR CARCINOMA
SCORE
SORAFENIB
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death globally. Sorafenib, a multi-tyrosine kinase inhibitor, remains the standard of care for patients with inoperable or advanced-stage HCC. In resource-limited settings without access to surgical or locoregional therapy, sorafenib may be the only option for treating HCC. However, due to a modest survival benefit, as well as the limiting cost of sorafenib in certain regions, appropriate selection of patients for treatment is essential. Evaluation of Barcelona Clinic Liver Cancer (BCLC) criteria in resource-limited settings is frequently unachievable due to a variety of reasons. Using a cohort from the South American liver research network (1336 HCC cases), we created a cost-effective prognostic scoring system to help identify patients likely to have a survival benefit on sorafenib treatment, using simple laboratory variable
Fil: Leathers, James S.. Vanderbilt University; Estados Unidos
Fil: Balderramo, Domingo. Universidad de Córdoba; España
Fil: Prieto, Jhon. Centro de Enfermedades Hepáticas y Digestivas; Colombia
Fil: Diehl, Fernando. Universidad de Córdoba; España
Fil: Gonzalez-Ballerga, Esteban. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina
Fil: Ferreiro, Melina R.. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina
Fil: Carrera, Enrique. Hospital Eugenio Espejo; Ecuador
Fil: Barreyro, Fernando Javier. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Nordeste; Argentina
Fil: Diaz Ferrer, Javier. Hospital Nacional Edgardo Rebagliati Martins; Perú
Fil: Singh, Dupinder. University of Minnesota; Estados Unidos
Fil: Mattos, Angelo Z.. Universidade Federal de Ciencias Da Saúde de Porto Alegre; Brasil
Fil: Carrilho, Flair. Universidade de Sao Paulo; Brasil
Fil: Debes, Jose D.. University of Minnesota; Estados Unidos
description Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death globally. Sorafenib, a multi-tyrosine kinase inhibitor, remains the standard of care for patients with inoperable or advanced-stage HCC. In resource-limited settings without access to surgical or locoregional therapy, sorafenib may be the only option for treating HCC. However, due to a modest survival benefit, as well as the limiting cost of sorafenib in certain regions, appropriate selection of patients for treatment is essential. Evaluation of Barcelona Clinic Liver Cancer (BCLC) criteria in resource-limited settings is frequently unachievable due to a variety of reasons. Using a cohort from the South American liver research network (1336 HCC cases), we created a cost-effective prognostic scoring system to help identify patients likely to have a survival benefit on sorafenib treatment, using simple laboratory variable
publishDate 2018
dc.date.none.fl_str_mv 2018-10
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/85699
Leathers, James S.; Balderramo, Domingo; Prieto, Jhon; Diehl, Fernando; Gonzalez-Ballerga, Esteban; et al.; PIB: A score to select sorafenib treatment candidates for hepatocellular carcinoma in resource-limited settings; Baqiyatallah Research Center; Hepatitis Monthly; 18; 10; 10-2018; 1-3
1735-143X
1735-3408
CONICET Digital
CONICET
url http://hdl.handle.net/11336/85699
identifier_str_mv Leathers, James S.; Balderramo, Domingo; Prieto, Jhon; Diehl, Fernando; Gonzalez-Ballerga, Esteban; et al.; PIB: A score to select sorafenib treatment candidates for hepatocellular carcinoma in resource-limited settings; Baqiyatallah Research Center; Hepatitis Monthly; 18; 10; 10-2018; 1-3
1735-143X
1735-3408
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/http://hepatmon.com/en/articles/82345.html
info:eu-repo/semantics/altIdentifier/doi/10.5812/hepatmon.82345
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Baqiyatallah Research Center
publisher.none.fl_str_mv Baqiyatallah Research Center
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269574647513088
score 13.13397

Publicaciones similares